Antibody, In-Vitro, In-Vivo and Scientist - Clinical Research Informer

China’s NMPA clears Transcenta’s IND for solid tumour treatment

Pharmaceutical Technology

JANUARY 4, 2023

TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody. In the syngeneic tumour model, the monoclonal antibody has also improved the checkpoint inhibitor’s anti-tumour activity. In the syngeneic tumour model, the monoclonal antibody has also improved the checkpoint inhibitor’s anti-tumour activity.

Antibody

Antibody In-Vivo In-Vitro Protein

News from AACR 2024: Sunday’s highlights

Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo

In-Vivo In-Vitro Antibody Protein

Evotec Partners with Alloy Therapeutics to Expand its Antibody Discovery Platform

The Pharma Data

DECEMBER 20, 2020

. PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS. ” ABOUT ALLOY THERAPEUTICS Alloy Therapeutics is a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all.

Antibody

Antibody In-Vivo In-Vitro Scientist

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.

Antibody

Antibody Gene Therapy Gene In-Vitro

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody

Antibody Engineer Protein Scientist

Immuno-Oncology Summit Europe 2023: Programme highlights

Drug Discovery World

JULY 3, 2023

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London.

Antibody

Antibody In-Vitro Engineer In-Vivo

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. The antibodies are conjugated to fluorochromes for them to be detected. The webinar also showed two examples of receptor occupancy assays conducted by Medpace for sponsors.

Clinical Trials

Clinical Trials Clinical Trials Trials Antibody

The evolution of assays for immuno-oncology research

Drug Discovery World

FEBRUARY 15, 2023

These have been the most promising form of antibodies being developed, with Ipilimumab (CTLA4 blocking) and Nivolumab (PD1 blocking) now approved by the US Food and Drug Administration (FDA) for more than nine cancer types. Half of people diagnosed with cancer in England and Wales survive their disease for 10 years or more (2010-11) 1.

Research

Research In-Vitro In-Vivo Development

Are organ-chips the future of preclinical research?

Drug Discovery World

OCTOBER 27, 2023

With cues from a diverse population of tissue-specific cell types, extracellular matrix proteins, and biomechanical forces, cells grown in organ-chips closely emulate their in vivo counterparts and replicate tissue-level functions. But can organ-chips entirely replace other models? Not yet, according to Ewart.

Research

Research Gene Therapy In-Vivo In-Vitro

What an innovation centre means for 3D biology

Drug Discovery World

NOVEMBER 16, 2022

In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. . 2D vs 3D . 2D biology has been used by pharmaceutical researchers for decades. 2D vs 3D .

Drugs

Drugs In-Vivo In-Vitro Scientist

How mice with humanised immune systems are advancing cell-based immunotherapy

Drug Discovery World

JULY 22, 2022

By Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences. To mitigate these risks, clinicians are turning to other immunomodulators, such as cell-based therapies, bispecific antibodies, and cytokine treatments. However, adverse effects such as cytokine release syndrome (CRS) and neurotoxicity still occur.

In-Vivo

In-Vivo Engineer In-Vitro Antibody

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

AUGUST 3, 2022

This is a common reaction within peptide chemistry and it has been approved by regulatory authorities for various antibody-drug conjugates 4. Currently, only a small number of CPP-based oligonucleotide delivery examples have been reported for in vivo application. However, this method does come with one major drawback.

Bioavailability

Bioavailability In-Vivo RNA In-Vitro

Clinical Research Informer

China’s NMPA clears Transcenta’s IND for solid tumour treatment

News from AACR 2024: Sunday’s highlights

Trending Sources

Evotec Partners with Alloy Therapeutics to Expand its Antibody Discovery Platform

Turning science into business: An optimised alternative to antibodies

What to expect from PEGS Europe 2023: Day 1

Immuno-Oncology Summit Europe 2023: Programme highlights

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

The evolution of assays for immuno-oncology research

Are organ-chips the future of preclinical research?

What an innovation centre means for 3D biology

How mice with humanised immune systems are advancing cell-based immunotherapy

Cell-penetrating peptides as a delivery system for oligonucleotides

Stay Connected